Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene

  title={Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene},
  author={Christoph Plass and Feng Yu and Li Yu and Matthew P Strout and Wa'el El‐Rifai and Erkki Elonen and Sakari Knuutila and Guido Marcucci and Donn C. Young and William A. Held and Clara Derber Bloomfield and Michael A. Caligiuri},
There is substantial evidence to suggest that aberrant DNA methylation in the regulatory regions of expressed genes may play a role in hematologic malignancy. In the current report, the Restriction Landmark Genomic Scanning (RLGS) method was used to detect aberrant DNA methylation (M) in acute myeloid leukemia (AML). RLGS-M profiles were initially performed using DNA from diagnostic, remission, and relapse samples from a patient with AML. Rp18, one of the eight spots found that was absent in… 

DNA methylation patterns at relapse in adult acute lymphocytic leukemia.

DNA methylation patterns are stable in a majority of patients with relapsed ALL, but a subset of patients acquire new methylation changes, in particular affecting cell cycle regulatory genes.

Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci.

Evidence for widespread aberrant methylation in AML is provided, with identification of novel methylation targets, epigenetic changes that appear unique to AML, and apparent preferential methylation on chromosome 11.

Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia

This study identified early aberrantly methylated genes as potential contributors to onset and progression of AML, underscoring the relevance of the mouse model for human AML.

Minimal Residual Disease in Acute Myeloid Leukemia

Because the fusion transcripts are thought to be specific to the leukemic cells, their detection in BM or blood from AML patients who achieve CR following intensive treatment has been used as a surrogate marker for minimal residual disease (MRD).

Quantitative analyses of DAPK1 methylation in AML and MDS

A refined DAPK1 methylation analysis in a large representative patient cohort of AML and MDS patients proofing almost complete absence of elevated DNA methylation is presented.

DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights.

An overview of current advances in deciphering the leukemic epigenome and its clinical relevance is provided and high-throughput analyses and genome-wide studies provide an optimal starting point for future epigenetic and integrative analyses that will further the development and use of predictive and prognostic epigenetic markers in acute myeloid leukemia.

DNA Methylation Markers in Patients with Gastrointestinal Cancers

The progress in the understanding of methylation in gastrointestinal tumors, the potential clinical applications ofmethylation-based markers and the process for the discovery and validation of highly specific and sensitive markers for the use in these applications are reviewed.

DNA methylation profiling: a new tool for evaluating hematologic malignancies.

These findings highlight the importance of DNA methylation in epigenetic control of early mammalian development as well as the role ofDNA methylation following embryogenesis, which is not resolved.

Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.

5-azacitidine(5-Aza)- a demethylating agent, could restore ATPsyn-β mRNA expression and increase the adriamycin sensitivity of primary leukemic cells from seven relapsed/ refractory AML patients.

The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia.

The increased regional DNA methylation demonstrated may then participate in or mark chromosomal changes associated with gene inactivation events that are central to the genesis and/or progression of human cancers.

High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.

The data indicate that high expression of wt1 mRNA is associated with a worse long-term prognosis and patients with high levels of wT1 had a significantly worse overall survival than those with not detectable or low levels.

Molecular biology of acute myeloid leukemia.

Observations support the notion that AML is heterogeneous at the molecular level, and suggest that clinicians will need to continue to take cytogenetic and molecular characteristics into consideration to optimize patient therapy.

HIC1 hypermethylation is a late event in hematopoietic neoplasms.

HIC1 methylation, therefore, seems to be a progression event in hematopoietic neoplasms.

Alterations in DNA methylation: a fundamental aspect of neoplasia.

Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors.

Comparison MS-RDA of one hepatocellular carcinoma and of background liver tissue of one mouse treated with a food carcinogen and a methylation-sensitive-representational difference analysis method, which is a promising approach to identify DNA fragments differentially methylated in two DNA sources.

Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR.

It is demonstrated that this technique is a rapid and efficient method that can be used to screen for altered methylation patterns in genomic DNA and to isolate specific sequences associated with these changes.

Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer.

The view that the short arm of human chromosome 11 is subjected to widespread regional hypermethylation in various human malignancies is supported.

DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas.

These findings provide a potential new molecular marker for two important human cancers (lung cancer and lymphomas) and suggest that there is a close relationship between abnormal CT gene methylation and developmental events for these tumors.